CAR-T-43

CAR-T-43 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by Pharos Biologicals (also known as Pharos Vaccine). Currently in the preclinical stage, the program is designed to treat both hematologic malignancies and solid tumors, specifically T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), and gastric adenocarcinoma. The therapy involves engineering a patient's T cells to express a chimeric antigen receptor that targets a specific, though currently undisclosed, antigen shared across these diverse cancer types. By leveraging the company's CAR-T platform, CAR-T-43 aims to provide a targeted immunotherapy option for patients with these aggressive leukemias and adenocarcinomas.